Overview

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.
Phase:
Phase 2
Details
Lead Sponsor:
Seres Therapeutics, Inc.
Collaborators:
INC Research
Syneos Health